Assessment of Serum Caspase-1, IL-10, and IL-18 Levels in Baghdad's Medical City in Women with Polycystic Ovary

Background: Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women. Caspase-1 is implicated in several important inflammatory diseases and controls adipocyte differentiation and insulin sensitivity. Interleukin10 (IL-10) is an anti-inflammatory cytokine and plays an important role in chronic inflammatory conditions. This study was planned to investigate the association between insulin resistance in (PCOS) and serum levels of caspase-1, IL-10, and IL-18. Methods: Fifty women with PCOS and forty healthy controls were evaluated in this controlled clinical study. Caspase-1 and IL-18, IL-10 levels, serum lipid sub-fractions, fasting glucose, fasting insulin, and other hormone levels were measured. Homeostasis model assessment (HOMA-IR) was used to estimate insulin resistance. Results: Regarding levels of obesity, the BMI of patients and controls was significantly different (P > 0.01). The tests of insulin, fasting glucose, HOMA, testosterone, progesterone, prolactin, LH, estradiol, SHBG, cholesterol, triglycerides, LDL, HDL, and VLDL all showed statistically significant changes. Research participants' serum FSH levels were greater than controls, but this difference was statistically insignificant. There was a highly significant difference in IL 10 and IL 18 levels. Additionally, PCOS patients had considerably greater Caspase-1 levels than controls. A significant positive link between age and caspase-1 (r = -0.296**, p = 0.036), a significant positive relationship between BMI and IL-18 (r = 0.338**, p = 0.017), and a significant positive relationship between IL-10 and VLDL levels (r = 0.529**, p = 0.00007) Conclusion: There was an association between caspas-1, IL-10, IL-18 and polycystic ovary syndrome-related insulin resistance. Many recent proteins and interleukins are now considered potential new markers of insulin resistance in diagnostic and therapeutic polycystic ovary syndrome.